Multiple Myeloma News
Venetoclax With 5-Azacytidine Effective in Treating Patients With Multiple Myeloma
Source: Pharmacy Times articles Venetoclax, which is approved for leukemia, blocks a function of the BCL-2 protein and has previously shown efficacy in a small proportion of patients with multiple myeloma. Read More
FDA Approves Cilta-Cel for Treatment of Relapsed, Refractory Multiple Myeloma
Source: Pharmacy Times articles The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy. Read More
Bispecifics in Multiple Myeloma: Insights on Operational Readiness and Patient Care
Source: Pharmacy Times articles Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some of the considerations for bispecifics in relation to facility readiness at different sites and among different stakeholders. Read More
Bone marrow stromal cells dictate lanosterol biosynthesis and ferroptosis of multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death
Source: Myeloma : nature.com subject feeds Post Content Read More
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
Source: Myeloma : nature.com subject feeds Post Content Read More
FDA Approval Expands Use of Abecma for Multiple Myeloma
Source: Myeloma - Hematology Advisor The Food and Drug Administration (FDA) has approved Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after 2 or more prior lines of therapy including an...
FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy
Source: Pharmacy Times articles The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines. Read More
Relapsed/Refractory Multiple Myeloma Treatment Advances With Three BiTE Therapy Options
Source: Pharmacy Times articles FDA-approved BiTE therapies for relapsed/refractory multiple myeloma show promising response rates, offering off-the-shelf alternatives to CAR T therapy. Read More
Preventive PBM Effective Against Oral Mucositis After Transplantation in MM
Source: Myeloma - Hematology Advisor Preventive photobiomodulation (PBM) appears to be more effective than a curative approach for mitigating the effects of oral mucositis (OM) among patients undergoing hematopoietic stem cell transplantation (HSCT) for multiple...